Engineered immune cells take on lupus in early trial
NCT ID NCT07318259
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-phase trial is testing a new type of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins (BCMA and CD70) on harmful cells. The study will enroll 18 adults to check safety and see if it can reduce lupus disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA/CD70 CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 18 people, so it's too soon to know if it works or is safe. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.